PubRank

Ira Shoulson

Author PubWeight™ 70.22‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Levodopa and the progression of Parkinson's disease. N Engl J Med 2004 5.44
2 Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002 4.60
3 Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 2004 3.73
4 Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006 3.57
5 Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008 2.79
6 Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009 2.46
7 Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology 2013 2.45
8 Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord 2012 2.18
9 Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain 2007 2.17
10 Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004 2.02
11 Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008 1.78
12 Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 2007 1.54
13 Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 2006 1.53
14 Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 2006 1.53
15 Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003 1.53
16 Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. Mov Disord 2002 1.48
17 Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010 1.45
18 Communicating clinical trial results to research participants. Arch Neurol 2008 1.16
19 Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord 2005 1.13
20 Fear of health insurance loss among individuals at risk for Huntington disease. Am J Med Genet A 2008 1.12
21 The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord 2008 1.12
22 We need something better, and we need it now: fetal striatal transplantation in Huntington's disease? Neurology 2002 1.10
23 A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008 1.07
24 Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet 2010 1.05
25 Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Mov Disord 2010 0.96
26 In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet 2010 0.93
27 Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Mov Disord 2011 0.90
28 Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord 2013 0.90
29 Mendelian randomization of serum urate and parkinson disease progression. Ann Neurol 2014 0.89
30 A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord 2009 0.89
31 Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord 2010 0.89
32 Altered cholesterol and fatty acid metabolism in Huntington disease. J Clin Lipidol 2010 0.88
33 Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics. Parkinsonism Relat Disord 2009 0.88
34 Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 2006 0.85
35 Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord 2011 0.84
36 Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol 2013 0.83
37 Preempting genetic discrimination and assaults on privacy: report of a symposium. Am J Med Genet A 2003 0.81
38 TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochem Biophys Res Commun 2012 0.81
39 Experimental neurotherapeutics: leaps and bounds. Arch Neurol 2002 0.80
40 A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. Mov Disord 2014 0.79
41 Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study. PLoS Curr 2011 0.79
42 A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol 2006 0.77
43 High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med 2005 0.77
44 Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine. Pharmacogenet Genomics 2014 0.77
45 Juvenile-onset huntington disease: a matter of perspective. Arch Neurol 2007 0.76
46 A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. Mov Disord 2009 0.76
47 HTRF analysis of soluble huntingtin in PHAROS PBMCs. Neurology 2013 0.75
48 Reply: Unusual DAT scan results. Mov Disord 2013 0.75
49 Measuring the effects of therapy in Parkinson disease. JAMA 2004 0.75
50 Data sharing for public health research: A qualitative study of industry and academia. Commun Med 2014 0.75
51 Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. Biomark Med 2015 0.75
52 In Memoriam: Robert J. Joynt, MD, PhD (1925-2012). Arch Neurol 2012 0.75
53 Reporting of randomized clinical trials and other population-based research: a priority of Archives of Neurology. Arch Neurol 2004 0.75